Business
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in non-small cell lung cancer - - Additional IMM-1-104 Phase 2a data updates and initiation of new IMM-1-104 combination arms expected in 2025; planning underway for po
About this update from Immuneering Corporation
[{"type":"image","alt":"Immuneering Corporation","displaySize":"","headline":null,"caption":"Immuneering Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/d79b6ec93b1d4423e8a0934e6a765313"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fGFUZ0nWiGak7K0u9vVc2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d79b6ec93b1d4423e8a0934e6a765313","width":300,"height":74}},"lazy":false},{"type":"text","content":"- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer -","length":190,"tagName":"p"},{"type":"text","content":"- Announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in non-small cell lung cancer -","length":172,"tagName":"p"},{"type":"text","content":"- Additional IMM-1-104 Phase 2a data updates and initiation of new IMM-1-104 combination arms expected in 2025; planning underway for potential IMM-1-104 global pivotal trial -","length":176,"tagName":"p"},{"type":"text","content":"- Named industry veteran Dr. Igor Matushansky as Chief Medical Officer -","length":72,"tagName":"p"},{"type":"text","content":"- Cash runway extended into 2026 -","length":34,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business updates.","length":363,"tagName":"p"},{"type":"text","content":"“We were delighted to report updates from our ongoing Phase 2a trial of IMM-1-104 in January 2025 demonstrating excellent response rates for IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients. Highlights of these data included an observed ORR of 43% and DCR of 86% for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) and an observed ORR of 50% for IMM-1-104 in combination with modified FOLFIRINOX (mFFX). Historic benchmarks for eithe...